Denosumab-associated hypocalcemia in a patient with chronic kidney disease and Paget's disease

Grasemann, 2013, Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease, J Clin Endocrinol Metab, 98, 3121, 10.1210/jc.2013-1143 Tanaka, 2017, Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget's disease: a case report, Oncol Lett, 13, 2105, 10.3892/ol.2017.5693 Appelman-Dijkstra, 2018, Paget's disease of bone, Best Pract Res Clin Endocrinol Metabol, 32, 657, 10.1016/j.beem.2018.05.005 Reid, 2016, Treatment of paget's disease of bone with denosumab: case report and literature review, Calcif Tissue Int, 99, 322, 10.1007/s00223-016-0150-6 Singer, 2014, Paget's disease of bone: an endocrine society clinical practice guideline, J Clin Endocrinol Metab, 99, 4408, 10.1210/jc.2014-2910 Hirao, 2011, [Denosumab as the potent therapeutic agent against Paget's disease of bone], Clin Calcium, 21, 1231 Schwarz, 2012, Paget's disease of the bone after treatment with Denosumab: a case report, Bone, 50, 1023, 10.1016/j.bone.2012.01.020 Skubitz, 2014, Giant cell tumor of bone: current treatment options, Curr Treat Options Oncol, 15, 507, 10.1007/s11864-014-0289-1 Xu, 2013, Denosumab and giant cell tumour of bone-a review and future management considerations, Curr Oncol, 20, e442, 10.3747/co.20.1497 Mak, 2014, A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab, J Bone Joint Surg Am, 96, 10.2106/JBJS.M.01332 Ueda, 2015, Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial, Ann Oncol, 26, 2149, 10.1093/annonc/mdv307 Polyzos, 2019, Off-label uses of denosumab in metabolic bone diseases, Bone, 129, 115048, 10.1016/j.bone.2019.115048 Jamal, 2011, Effects of denosumab on fracture and bone mineral density by level of kidney function, J Bone Miner Res, 26, 1829, 10.1002/jbmr.403 Salim, 2018, Denosumab-associated severe hypocalcemia in a patient with chronic kidney disease, Am J Med Sci, 355, 506, 10.1016/j.amjms.2017.09.008 Huynh, 2016, Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting, Pharmacoepidemiol Drug Saf, 25, 1274, 10.1002/pds.4045 McCormick, 2012, Severe hypocalcemia following denosumab injection in a hemodialysis patient, Am J Kidney Dis, 60, 626, 10.1053/j.ajkd.2012.06.019 Block, 2012, A single-dose study of denosumab in patients with various degrees of renal impairment, J Bone Miner Res, 27, 1471, 10.1002/jbmr.1613 Lung, 2022, Calcitriol Strickling, 2019, Severe, symptomatic hypocalcemia due to denosumab administration: treatment and clinical course, Case Rep Nephrol Dial, 9, 33, 10.1159/000499824